Effects of dopamine agonists on delayed response performance in chronic low-dose MPTP-treated monkeys

https://doi.org/10.1016/0091-3057(94)90522-3Get rights and content

Abstract

Monkeys exposed to low doses of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) develop difficulty in performing a previously learned delayed response (DR) task. In the present group of animals, performance deficits were manifested as a combination of mistakes or incorrect responses and no response errors, trials on which the animals failed to respond. Methylphenidate and the dopamine D2 receptor agonist LY-171555, at low doses, decreased the number of no-response errors but not mistakes. The partial D1 agonist SKF-38393 had no effects on no-response errors or mistakes. Thus, behavioral deficits associated with decreased task persistent may be amenable to treatment with dopamine agonist, and particularly D2 agonists, while cognitive performance per se may not be improved by such drugs. The similarities between this primate model and the cognitive/behavioral deficits associated with early Parkinson's disease and attention deficit hyperactivity disorder suggest that this may be a useful model for testing hypotheses concerning the pharmacological treatment of these disorders.

References (51)

  • J.R. Taylor et al.

    Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys

    Eur. J. Pharmacol.

    (1991)
  • A.J. Zametkin et al.

    Neurobiology of attention deficit disorder with hyperactivity: Where have we come in 50 years?

    J. Am. Acad. Child Adolesc. Psychiatry

    (1987)
  • A.F.T. Arnsten et al.

    The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: Evidence for alpha-2 receptor subtypes

    J. Neurosci.

    (1988)
  • A.F.T. Arnstem et al.

    Behavioral and receptor binding analysis of the alpha-2 adrenergic agonist, 5-bromo-6[2-imidazoline-2-yl amino] quinoxaline (UK-14304): Evidence for cognitive enhancement at an alpha-2 adrenoceptor subtype

    Neuropharmacology

    (1991)
  • R.A. Barkley et al.

    Attention deficit disorder with and without hyperactivity: Clinical response to three dose levels of methylphenidate

    Pediatrics

    (1991)
  • K. Battig et al.

    Comparison of the effects of frontal and caudate lesions on delayed response and alternation in monkeys

    J. Comp. Psychol.

    (1960)
  • P.J. Bedard et al.

    Levodopa-induced dyskinesia: Facts and fancy. What does the MPTP monkey model tell us?

    Can. J. Neurol. Sci.

    (1992)
  • S. Boyce et al.

    Differential effects of D1 and D2 agonists in MPTP-treated primates: Functional implications for Parkinson's disease

    Neurology

    (1990)
  • A. Braun et al.

    Selective D1 dopamine receptor agonist treatment of Parkinson's disease

    J. Neural. Transm.

    (1987)
  • R.S. Burns et al.

    A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

  • M.P. Caligiuri et al.

    Sensorimotor disinhibition in Parkinson disease: Effects of levodopa

    Ann. Neurol.

    (1992)
  • L. Charles et al.

    Effects of methylphenidate on hyperactive children's ability to sustain attention

    Pediatrics

    (1979)
  • S.P. Close et al.

    Failure of SKF-38393-A to relieve parkinsonian symptoms induced by MPTP in the marmoset

    Br. J. Pharmacol.

    (1985)
  • E.F. Domino et al.

    N-methyl-D-aspartate receptor antagonism and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced hemiparkinsonian monkeys

    J. Pharmacol. Exp. Ther.

    (1993)
  • F.G. Erbaugh

    Neuropsychiatric sequelae of acute epidemic encephalitisin children

    Am. J. Dis. Child.

    (1923)
  • Cited by (44)

    • Methylphenidate does not enhance visual working memory but benefits motivation in macaque monkeys

      2016, Neuropharmacology
      Citation Excerpt :

      Rajala et al. (2012) reported a dose-dependent increase in the amount of time monkeys engaged in the task. Schneider et al. (1994) reported that DA-depleted (MPTP-treated) monkeys seemed more focused while performing a delayed response task after MPH treatment, which decreased the occurrence of omissions, without a significant effect on errors. Overall, MPH may exert its effects by enhancing task engagement.

    • Methods and Models of the Nonmotor Symptoms of Parkinson Disease

      2015, Movement Disorders: Genetics and Models: Second Edition
    • Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model

      2009, Brain Research
      Citation Excerpt :

      The animals also develop deficits in performing delayed response and delayed matching to sample tasks (Schneider and Kovelowski, 1990; Schneider and Roeltgen, 1993), although deficits on these tasks are more attentional-related than memory-related per se (Decamp et al., 2004). Although dopaminergic therapies have had little or no positive effect on performance of these tasks in these animals (Schneider et al., 1994, 1998), nicotine and nicotinic receptor subtype selective agonists have shown efficacy in ameliorating many of the cognitive deficits in chronic low dose MPTP-treated animals (Decamp and Schneider, 2006; Schneider et al., 1998, 1999, 2003b). However, since nicotinic therapies would be used clinically as adjuncts to levodopa administration it is important to know how these two therapies interact.

    View all citing articles on Scopus
    View full text